CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
EUROPE
APAC
CANADA

About Us

Conference

Partner With Us

  • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Drug Discovery
    Antibodies
    BioTech
    Cell and Gene Therapy
    Clinical Trial
    Drug Discovery and Development
    Life Science AI
    Regenerative Medicine
    Therapeutics
  • Biomanufacturing
    Biomanufacturing
    Bioprocessing
    Blood Bank
    CDMO
    Clinical Laboratory
    CRO
    Life Science Testing
    Skin Care
    Supplements
  • Business Services
    Life Science Consulting
    Life Science Facility Service
    Life Science Financial Services
    Life Science Marketing
    Life Science Recruitment Firms
    Pharma Wholesale and Distribution
    Pharmacy Management
    Regulatory and Compliance
    Regulatory Services
  • Leadership Perspectives
  • Innovation Insights
  • Research
  • News
  • Magazines
  • CXO Awards
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

A featured contribution from Leadership Perspectives: a curated forum reserved for leaders nominated by our subscribers and vetted by our Life Sciences Review Advisory Board.

Ltd.

Takaki Demichi, Head Of Department, Sparks Asset Management Co.

Growth Potential Of The Japanese Venture Capital Market

Takaki Demichi

Takaki Demichi

Japan Growth Pathfinder

We believe that Japan's venture capital (VC) market offers a significant investment opportunity going forward. Although the total value of venture-related investments made in the U.S. is much higher than in Japan, we see this massive difference as an opportunity. In 2022, U.S. startups raised 194.4 billion dollars compared to only 6.7 billion dollars by Japanese startups, which is about 3 percent of the U.S. total. Experts usually cite a lower number of startups and the fact that Japanese startups typically only focus on the Japanese market as two main reasons for this funding disparity. When comparing U.S. and Japanese startups operating within the same industry, valuations for U.S. startups are multiple times higher than for their Japanese peers. We believe that many Japanese startups are extremely undervalued.


Signs that this gap has the potential to narrow in the future have begun to emerge. The first sign of this is a change in the mindsets of the younger generation in Japan. Traditionally, large corporations and the government were the best employment options for talented students and young people. However, in recent years, many talented young people have started their businesses. Furthermore, these new businesses are focusing more on the global economy. These young founders realize that Japan has become a mature country, and if they want their companies to grow, they have no choice but to look to the international markets.


Secondly, compared to the rest of the world, the cost of hiring talented Japanese engineers is relatively cheaper. In the latter half of the 20th century, Japan transformed into a major exporter fueled by a cheap labor force producing high-quality goods. The recent depreciation of the yen, combined with dramatic changes in its industrial structure, has increased the likelihood that Japan's global role will evolve. We believe that its startups will play a major role.


 


Lastly, the Japanese government is more proactive. One of the priorities of Prime Minister Kishida’s cabinet is to increase support for startups. The importance of such governmental involvement is critical, as evident in the case of neighboring China, India, as well South Korea, where government support has helped the venture capital industry to flourish in each of these countries.


Understanding SPARX Private Equity Strategies


Since its founding in 1989, SPARX has created new investment strategies for our global investors seeking to capitalize on opportunities in Japan’s stock markets. As the navigator of the world’s capital, we aim to play the same role in Japan’s private equity market.


Many talented young people have started their businesses. Furthermore, these new businesses are focusing more on the global economy


With support from our cornerstone investors, Toyota Motor Corporation and Sumitomo Mitsui Banking Corporation, we started the Mirai Creation strategy (“Mirai” means “future” in Japanese), which invests in startups around the world (mainly Japan). We continue to expand our business, which now includes a fund that invests in startups focused on space, and another fund that buys manufacturing companies with superior technology and aims to increase their corporate value.


Over the past few years, our private equity strategies have grown to become some of the largest in Japan with total assets under management of approximately 1.5 billion dollars.


The articles from these contributors are based on their personal expertise and viewpoints, and do not necessarily reflect the opinions of their employers or affiliated organizations.

Editorial Lens

Japan’s venture capital market carries growing significance for life sciences investors watching talent, valuation and government support reshape startup opportunity. Demichi’s perspective helps sector stakeholders look beyond funding gaps and assess Japan’s evolving role in global innovation with greater editorial clarity.

The Leadership Perspectives forum brings together voices shaping the future of life sciences. It features leaders who are advancing change across the industry through strategic leadership and applied insight.
EDITOR'S CHOICE
  • Willis Towers Watson

    ICON [NASDAQ: ICLR]

    The Significant Increase in Demand for Clinical Research Associates (CRAs)

    Helen Yeardley, Executive Vice President, ICON [NASDAQ: ICLR]

  • Willis Towers Watson

    PacBio [NASDAQ: PACB]

    The Talent - Culture Continuum: How to Manage an Innovation Culture Amid Growth and Change

    Alvin Hom, Head of Global Talent Acquisition, PacBio [NASDAQ: PACB]

  • Willis Towers Watson

    Repligen Corp [NASDAQ: RGEN]

    Gene Therapy-Therapeutic Viral Vectors; Manufacturing, Challenges, and Innovation

    Rachel Legmann, PhD, Senior Director of Technology, Gene Therapy, Repligen Corp

  • Willis Towers Watson

    Ionis Pharmaceuticals [NASDAQ: IONS]

    Bridging the Diversity Divide

    Victoria Sanjurjo, Medical Director, Clinical Development, Ionis Pharmaceuticals, Inc [NASDAQ: IONS]

Life Sciences Review
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review. All rights reserved. Headquartered in Fort Lauderdale, FL, USA.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/leadership-perspective/growth-potential-of-the-japanese-venture-capital-market-nwid-1977.html